RedixFi
Pre-openNIFTY24,536.6+2.4%
Market feed live
Log in

JBCHEPHARM · J B Chemicals and Pharma · Biotechnology & Drugs

JBCHEPHARM · J B Chemicals and Pharma · Biotechnology & Drugs

₹2,487.6+1.1%

As of 14 Jul close

52-week range. Price history incomplete · as of 14 Jul 2026

Price chartDaily closes on the stock page.

Stock Condition:Pro

Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.

Full signal detail →

Fundamentals as of 16 Oct 2026

Promoter holding rose this quarter

Revenue (latest Q)

₹904 Cr

Revenue YoY

PAT YoY

-30.4%

Operating margin

Revenue, last 5 quarters

Source: Yahoo Finance, as of 31 Mar 2026

P/E (TTM)

P/B

9.3

P/S (TTM)

Not available from data source

Sector P/E

Not available from data source

Dividend yield

+0.9%

Source: Yahoo Finance, as of 29 Oct 2026

No peer comparison data on file for JBCHEPHARM.

Promoter

stable

FII

rising 1q

MF

19.00% (-0.22pp)

falling 2q

Insider trades

DateInsiderTypeQtyValue
25 Jun 2026Parmeshwar Bhawarlalji BangSELL1,300₹29.19 lakh
25 Jun 2026Parmeshwar Bhawarlalji BangSELL1,300₹29.19 lakh
17 Mar 2026Sujay Kamlakar RajhansSELL11,811₹2.49 Cr
19 Feb 2026Stewart Graham BarkerBUY31,160₹6.21 Cr
03 Feb 2026Torrent Pharmaceuticals LimitedBUY92,490₹14.8 Cr
03 Feb 2026Stewart Graham BarkerSELL92,490₹14.8 Cr
30 Jan 2026Stewart Graham BarkerBUY92,490₹5.55 Cr
23 Jan 2026Sanjeev Kailash MishraBUY9,894₹1.58 Cr
23 Jan 2026Anand PrasadBUY19,782₹3.17 Cr
23 Jan 2026Manoj Mohan ChitnisBUY41,548₹6.65 Cr
23 Jan 2026Sridhar Pala BharadwajBUY51,934₹8.31 Cr
23 Jan 2026Bharat Bachubhai DhananiBUY62,321₹9.97 Cr
23 Jan 2026Jason Nestor Vincent DSouzaBUY61,934₹9.91 Cr
23 Jan 2026Sujay Kamlakar RajhansBUY92,489₹14.8 Cr
23 Jan 2026Narayan Prasad SarafBUY1,68,468₹26.95 Cr
23 Jan 2026Pradeep Kumar SinghBUY1,73,421₹27.75 Cr
23 Jan 2026Dilip Singh RathoreBUY2,17,534₹34.81 Cr
23 Jan 2026Nikhil Ashokkumar ChopraBUY19,16,596₹307 Cr

Bulk/block deals

No bulk/block deals in the last 12 months.

News timeline

No related news.

Concalls & investor presentations

AI-generated

No concall transcripts or investor presentations recorded yet.

AI Summary of Annual Report

AI-generated
FY2025-26263 pages

JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) reported a focus on sustainable growth, operational efficiency, and disciplined capital allocation in FY2025-26. The company completed a merger with a subsidiary, enhancing product offerings and operational efficiencies. No material defaults or regulatory penalties were noted, and statutory dues were generally up to date. The company maintains compliance with corporate governance and has no unresolved disputes over significant statutory dues. Key risks include pending tax disputes and reliance on accurate revenue recognition.

  • Completed merger with subsidiary to enhance product portfolio and operational efficiency.
  • No defaults or regulatory penalties noted; statutory dues generally up to date.
  • Pending tax disputes under appeal, but no material impact on liquidity or solvency.
  • Emphasis on sustainable growth, operational efficiency, and disciplined capital allocation.

Key takeaway: JB Chemicals & Pharmaceuticals Limited demonstrates strong operational focus and compliance, with pending tax disputes as the primary risk.

The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.

Filed with NSE · 25 May 2026View source filing →

Governance disclosures

AI-generated

Needs attention

No item of a kind that needs attention was stored for this company.

Promoter Share Pledge

1 occurrence

Recent (last 12 months)

Structured Filing Data (NSE Pledge Disclosure)17 Jul 2026

1.26% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-17).

Open full Signal Dashboard →